Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

BGI and GT Life Sciences Announce Complete Sequencing of CHO Genome

Published: Monday, January 10, 2011
Last Updated: Monday, January 10, 2011
Bookmark and Share
CHO whole genome sequence data has been assembled and early access is now available.

GT Life Sciences, Inc., and BGI announced that they have successfully completed for the first time the sequencing of the Chinese hamster ovary (CHO-K1) genome. Early access to the genome is now available.

Chinese hamster ovary cell lines, or CHO cell lines, are mammalian cells that have been derived from the ovary of the Chinese hamster and are used widely in biological research and in the production of therapeutic proteins. Today at least 70% of all therapeutic proteins are produced in CHO cells.

Currently the worldwide market for therapeutic proteins totals approximately $100 billion. The sequencing of the CHO genome will yield a wealth of new information and understanding of CHO cell functions, accelerating the discovery and development of new recombinant protein therapeutics. By increasing the productivity of CHO cell lines used in many pharmaceutical expression systems, production costs can be reduced.

"Sequencing the CHO genome represents a major milestone in optimizing this widely used mammalian cell line both for pharmaceutical research and for production of therapeutic proteins," stated Bernhard Palsson, Ph.D., Galetti Professor of Bioengineering and Adjunct Professor Medicine at the University of California, San Diego. "This newly available knowledge will bring multiple benefits, including media optimization and improved cell growth, protein production, glycosylation, and cell line engineering. Ultimately, it brings genome-scale science to CHO-based production of biopharmaceuticals."

GT Life Sciences' established CHOmics business platform for metabolic modeling and engineering of mammalian cells has already proven effective in optimizing CHO cell media and developing novel selectable markers. "The availability of the sequence together with a complete genome-scale model of CHO metabolism is proving to be a powerful tool that will allow us to deliver the next generation of process technologies for biopharmaceutical production in CHO and other mammalian cell lines," added Iman Famili, Ph.D., Sr. Director, Research and Development at GT Life Sciences.

"The complete sequencing of CHO-K1 genome is a major step forward in the application of genomics in the production of biopharmaceuticals," stated Dr. Jun Wang, Executive Director of BGI. "GT's CHOmics platform provides a valuable foundation for CHO genomics research and the study of CHO cell metabolism. BGI's sequencing and bioinformatics capabilities, combined with GT's CHOmics platform, will contribute to the transformation of biopharmaceutical production."


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,900+ scientific posters on ePosters
  • More Than 4,200+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

BGI Opens Genome Research Center in Europe
The company opens its first European Genome Research Center located in Copenhagen Bio Science Park (COBIS).
Friday, February 10, 2012
Scientists Complete Sequencing Tibetan Antelope Genome
The genome sequencing is expected to explain the pathogenesis of chronic plateau sickness.
Monday, December 28, 2009
Beijing Genomics Institute Signs Global Site License with CLC bio for Sequencing Software Platform
The global site license agreement, for CLC Genomics Workbench, covers all researchers at all BGI sites, both inside and outside of China.
Friday, July 04, 2008
Scientific News
Food Triggers Creation of Regulatory T Cells
IBS researchers document how normal diet establishes immune tolerance conditions in the small intestine.
Light Signals from Living Cells
Fluorescent protein markers delivered under high pressure.
Counting Cancer-busting Oxygen Molecules
Researchers from the Centre for Nanoscale BioPhotonics (CNBP), an Australian Research Centre of Excellence, have shown that nanoparticles used in combination with X-rays, are a viable method for killing cancer cells deep within the living body.
Therapeutic Approach Gives Hope for Multiple Myeloma
A new therapeutic approach tested by a team from Maisonneuve-Rosemont Hospital (CIUSSS-EST, Montreal) and the University of Montreal gives promising results for the treatment of multiple myeloma, a cancer of the bone marrow currently considered incurable with conventional chemotherapy and for which the average life expectancy is about 6 or 7 years.
Cellular 'Relief Valve'
A team led by scientists at The Scripps Research Institute (TSRI) has solved a long-standing mystery in cell biology by showing essentially how a key “relief-valve” in cells does its job.
Genomic Signature Shared by Five Types of Cancer
National Institutes of Health researchers have identified a striking signature in tumor DNA that occurs in five different types of cancer.
Protein Protects Against Flu in Mice
The engineered molecule doesn’t provoke inflammation and may hail a new class of antivirals.
Cat Stem Cell Therapy Gives Humans Hope
By the time Bob the cat came to the UC Davis veterinary hospital, he had used up most of his nine lives.
Crowdfunding the Fight Against Cancer
From budding social causes to groundbreaking businesses to the next big band, crowdfunding has helped connect countless worthy projects with like-minded people willing to support their efforts, even in small ways. But could crowdfunding help fight cancer?
Switch Lets Salmonella Fight, Evade Immune System
Researchers at the University of Illinois at Chicago have discovered a molecular regulator that allows salmonella bacteria to switch from actively causing disease to lurking in a chronic but asymptomatic state called a biofilm.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!